News for NXTC Stock

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 NextCure Provides Business Update and Reports First Quarter 2025 Financial Results NextCure to Present at 24th Annual Needham Virtual Healthcare Conference NextCure Provides Business Update and Reports Full Year 2024 Financial Results NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers NextCure Announces Acceptance of IND Application for LNCB74 NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 NextCure Provides Business Update and Reports First Quarter 2024 Financial Results NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024 NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference NextCure Provides Business Update and Reports Full Year 2023 Financial Results NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury NextCure Provides Year-End Clinical Pipeline Updates NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting NextCure to Present at the JMP Securities Life Sciences Conference NextCure Provides Business Update and Reports First Quarter 2023 Financial Results NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference NextCure Provides Business Update and Reports Full Year 2022 Financial Results NextCure to Present at SVB Securities Global Biopharma Conference NextCure to Present at Upcoming Investor Conferences NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting NextCure Provides Update and Reports Third Quarter 2022 Financial Results NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors NextCure to Present at the Ladenburg Thalmann Healthcare Conference NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting NextCure to Present at the JMP Securities Life Sciences Conference NextCure Provides Business Update and Reports First Quarter 2022 Financial Results NextCure to Present at the BofA Securities 2022 Healthcare Conference NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation NextCure to Present at 21st Annual Needham Virtual Healthcare Conference NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting NextCure to Present at The JMP Securities Hematology and Oncology Summit NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update NextCure Announces Presentations on Targets in Development by Collaborators at American Society of Hematology Annual Meeting NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021 NextCure Announces Three New Members of its Scientific Advisory Board NextCure Announces Publication of Preclinical Data for NC410 NextCure Announces New Appointments to its Board of Directors NextCure to Give Three Presentations at Society for Immunotherapy of Cancer Annual Meeting NextCure to Present at the H.C. Wainwright 23rd Annual Global Investment Conference NextCure to Present at the 19th Annual Morgan Stanley Global Healthcare Conference NextCure Reports Second Quarter 2021 Financial Results NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410 NextCure to Present at the JMP Securities Life Sciences Conference NextCure to Present Trials in Progress Poster for NC410 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting NextCure Reports First Quarter 2021 Financial Results NextCure to Present at the BofA Securities 2021 Virtual Health Care Conference NextCure to Present at the 7th Annual Truist Securities Life Sciences Summit NextCure Presents Preclinical Data for NC762 at American Association for Cancer Research (AACR) Annual Meeting 2021 NextCure to Present at the 20th Annual Needham Virtual Healthcare Conference NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results REMINDER: NextCure to Host Virtual R&D Update Event on March 4, 2021 NextCure to Host Virtual R&D Update Event on March 4, 2021 Dr. Han Myint Appointed as NextCure’s Chief Medical Officer NextCure Provides Updates on NC318 Clinical Program NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference NextCure Reports Third Quarter 2020 Financial Results NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors NextCure to Present at Morgan Stanley Virtual 18th Annual Global Healthcare Conference NextCure Reports Second Quarter 2020 Financial Results NextCure to Present at BTIG Virtual Biotechnology Conference NextCure Initiates Phase 1/2 Clinical Study of NC410, a Novel Immunomedicine, for Solid Tumors NextCure to Present at BofA Securities Virtual Health Care Conference NextCure Provides an Interim Update of the Phase 2 Portion of the NC318 Monotherapy Phase 1/2 Trial and Announces Departure of Chief Medical Officer NextCure Reports First Quarter 2020 Financial Results